Advertisement

Clinical Pharmacokinetics

, Volume 57, Issue 7, pp 817–829 | Cite as

Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention

  • He-Ping Lei
  • Xi-Yong Yu
  • Hong Wu
  • Yan-Hong Kang
  • Wan-Ping Zhong
  • Li-Yun Cai
  • Meng-Zhen Zhang
  • Ji-Yan Chen
  • Li-Ping Mai
  • Qing-Shan Ding
  • Min Yang
  • Shi-Long ZhongEmail author
Original Research Article

Abstract

Introduction and Objective

The relationship between either paraoxonase 1 (PON1) gene promoter DNA methylation or genetic variations and bleeding or major adverse cardiac events after dual antiplatelet therapy has been incompletely characterized. We aimed to systematically investigate the role of genetic variations and DNA methylation of the PON1 CpG island promoter on the clinical outcomes of dual antiplatelet therapy for patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI).

Methods

This study included 653 patients with CAD undergoing PCI and receiving dual antiplatelet therapy. Genomic DNAs were isolated from whole blood and were genotyped for the three single nucleotide polymorphisms (SNPs) of the PON1 gene. The DNA methylation levels in the PON1 promoter region were determined by bisulfite sequencing or pyrosequencing at five CpG sites (positions −142, −161, −163, −170, and −184 from the transcription start site). Clopidogrel and its metabolites in plasma were examined using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), and platelet function analysis was performed using the VerifyNow assay.

Results

Statistically significant associations between methylation levels at five PON1 CpG sites and bleeding were observed: −184 [odds ratio (OR) 0.98, 95% confidence interval (CI) 0.96–1.00, p = 0.028]; −170 (OR 0.99, 95% CI 0.97–1.00, p = 0.048); −163 (OR 0.98, 95% CI 0.96–1.00, p = 0.029); −161 (OR 0.98, 95% CI 0.97–1.00, p = 0.026); and −142 (OR 0.98, 95% CI 0.97–1.00, p = 0.042) at a false discovery rate of <5%. Statistical analysis also revealed that aspirin reaction units (ARUs) were significantly associated with PON1 methylation level at CpG site −163 (p = 0.0342). The ARUs of patients with the PON1 126 CC genotype was 527 ± 94, which was higher than the ARUs (473 ± 89) of patients with the 126 CG genotype (p = 0.0163). Multivariate logistic regression analysis indicated that the PON1 methylation level at CpG site −161 (OR 0.95, 95% CI 0.92–0.98, p = 0.002) and the use of angiotensin-converting enzyme inhibitors (OR 0.48, 95% CI 0.26–0.89, p = 0.021) were associated with a decreased risk of bleeding events.

Conclusions

Hypomethylation of CpGs in the PON1 promoter may be a weak, albeit statistically significant, risk factor of bleeding after dual antiplatelet therapy. Further large-scale studies are needed to verify our results.

Notes

Compliance with Ethical Standards

Funding

This work was supported by the National Nature Science Foundation of China (Nos. 81373486, 81673514, 81330007, 81202602, U1601227), Science and Technology Development Projects of Guangdong Province, China (Nos. 2016B090918114, 2013B021800157), and Science and Technology Development Projects of Guangzhou, Guangdong, China (201510010236, 201604020096).

Conflict of interest

He-Ping Lei, Xi-Yong Yu, Hong Wu, Yan-Hong Kang, Wan-Ping Zhong, Li-Yun Cai, Meng-Zhen Zhang, Ji-Yan Chen, Li-Ping Mai, Qing-Shan Ding, Min-Yang, and Shi-Long Zhong declare that they have no conflicts of interest that might be relevant to the contents of this article.

Ethical Approval

This study was performed in compliance with the Declaration of Helsinki and was approved by the Medical Ethical Review Committee of the Guangdong General Hospital.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

40262_2017_595_MOESM1_ESM.docx (27 kb)
Supplementary material 1 (DOCX 28 kb)

References

  1. 1.
    Riley RF, Don CW, Powell W, Maynard C, Dean LS. Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes. 2011;4(2):193–7.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995;11(3):221–7.PubMedGoogle Scholar
  4. 4.
    Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007;120(3):323–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–16.CrossRefPubMedGoogle Scholar
  7. 7.
    Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61(8):872–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol. 2009;103(3 Suppl):27A–34A.CrossRefPubMedGoogle Scholar
  10. 10.
    Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol. 1998;9(4):319–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Shih DM, Lusis AJ. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol. 2009;20(4):288–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17(1):110–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Xie C, Ding X, Gao J, Wang H, Hang Y, Zhang H, et al. The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet Genom. 2014;24(4):204–10.CrossRefGoogle Scholar
  14. 14.
    Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneetrithep B, et al. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One. 2014;9(10):e110188.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kang YH, Lao HY, Wu H, Lai WH, Li XX, Yu XY, et al. Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. Eur J Clin Pharmacol. 2013;69(8):1511–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Santanam N, Parthasarathy S. Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Atherosclerosis. 2007;191(2):272–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Blatter-Garin MC, Kalix B, De Pree S, James RW. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia. 2003;46(4):593–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Jaichander P, Selvarajan K, Garelnabi M, Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008;49(10):2142–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Davila CD, Vargas F, Huang KH, Monaco T, Dimou A, Rangaswami J, et al. Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events. Platelets. 2015;26(7):651–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Tang QJ, Lin HM, He GD, Liu JE, Wu H, Li XX, et al. Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. Pharmacogenomics. 2016;17(14):1503–17.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhong WP, Wu H, Chen JY, Li XX, Lin HM, Zhang B, et al. A genome-wide association study identifies novel genetic loci that modify antiplatelet effects and pharmacokinetics of clopidogrel. Clin Pharmacol Ther. 2017;101(6):791–802.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057–68.CrossRefPubMedGoogle Scholar
  24. 24.
    Vanderkraats ND, Hiken JF, Decker KF, Edwards JR. Discovering high-resolution patterns of differential DNA methylation that correlate with gene expression changes. Nucl Acid Res. 2013;41(14):6816–27.CrossRefGoogle Scholar
  25. 25.
    Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5’ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001;68(6):1428–36.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 2001;11(1):77–84.CrossRefPubMedGoogle Scholar
  27. 27.
    Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54(12):1041–57.CrossRefPubMedGoogle Scholar
  28. 28.
    Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73(15):1681–709.CrossRefPubMedGoogle Scholar
  29. 29.
    Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genom. 2010;20(7):463–5.Google Scholar
  30. 30.
    Takahashi O. Inhibition of phylloquinone epoxide reductase by BHT quinone methide, salicylic acid and alpha-tocopherolquinone. Biochem Pharmacol. 1988;37(14):2857–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, et al. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J Thromb Thrombolysis. 2016;41(3):374–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol. 2012;25(2):348–56.CrossRefPubMedGoogle Scholar
  33. 33.
    Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–62.CrossRefPubMedGoogle Scholar
  34. 34.
    Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–36.CrossRefPubMedGoogle Scholar
  35. 35.
    De Bustos C, Ramos E, Young JM, Tran RK, Menzel U, Langford CF, et al. Tissue-specific variation in DNA methylation levels along human chromosome 1. Epigenetics Chromatin. 2009;2(1):7.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wright RO, Schwartz J, Wright RJ, Bollati V, Tarantini L, Park SK, et al. Biomarkers of lead exposure and DNA methylation within retrotransposons. Environ Health Perspect. 2010;118(6):790–5.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Bock C, Paulsen M, Tierling S, Mikeska T, Lengauer T, Walter J. CpG island methylation in human lymphocytes is highly correlated with DNA sequence, repeats, and predicted DNA structure. PLoS Genet. 2006;2(3):e26.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • He-Ping Lei
    • 1
    • 2
  • Xi-Yong Yu
    • 1
    • 3
  • Hong Wu
    • 4
  • Yan-Hong Kang
    • 1
  • Wan-Ping Zhong
    • 1
    • 2
  • Li-Yun Cai
    • 1
    • 2
  • Meng-Zhen Zhang
    • 1
    • 2
  • Ji-Yan Chen
    • 1
    • 2
  • Li-Ping Mai
    • 1
    • 2
  • Qing-Shan Ding
    • 1
    • 2
  • Min Yang
    • 1
    • 2
  • Shi-Long Zhong
    • 1
    • 2
    Email author
  1. 1.Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong General HospitalGuangdong Academy of Medical SciencesGuangzhouPeople’s Republic of China
  2. 2.School of MedicineSouth China University of TechnologyGuangzhouPeople’s Republic of China
  3. 3.School of Pharmaceutical SciencesGuangzhou Medical UniversityGuangzhouPeople’s Republic of China
  4. 4.Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations